Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP 0233278 and TASP 0390325
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Vasopressin V 1B receptor antagonists may be effective for the treatment of depression and anxiety and the objective of this study was to characterize the pharmacological profiles of two newly synthesized arginine vasopressin receptor 1 B (V 1B receptor) antagonists, TASP 0233278 and TASP 0390325. Experimental Approach: We investigated the in vitro profiles of TASP 0233278 and TASP 0390325. In addition, the effect of TASP 0390325 on the increase in plasma adrenocorticotropic hormone (ACTH) levels induced by corticotropin‐releasing factor (CRF)/desmopressin (d DAVP) was investigated. We also investigated the antidepressant and anxiolytic profiles of TASP 0233278 and TASP 0390325 in animal models. Key Results: Both TASP 0233278 and TASP 0390325 showed a high affinity and potent antagonist activity for V 1B receptors. Oral administration of TASP 0390325 antagonized the increase in plasma ACTH levels induced by CRF/d DAVP in rats, indicating that TASP 0390325 blocks the anterior pituitary V 1B receptor in vivo. Oral administration of TASP 0233278 or TASP 0390325 also exerted antidepressant effects in two models of depression (a forced swimming test and an olfactory bulbectomy model). Moreover, TASP 0233278 improved depressive‐like behaviour induced by repeated treatment with corticosterone, a model that has been shown to be resistant to treatment with currently prescribed antidepressants. In addition to depression models, TASP 0233278 or TASP 0390325 exerted anxiolytic effects in several anxiety models (social interaction, elevated plus‐maze, stress‐induced hyperthermia, separation‐induced ultrasonic vocalization and sodium lactate‐induced panic‐like responses in panic‐prone rats). Conclusion: TASP 0233278 and TASP 0390325 are potent and orally active V 1B receptor antagonists with antidepressant and anxiolytic activities in rodents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 1×
“Patients with MDD also exhibit increased levels of CSF corticotropin-releasing factor (CRF) (Nemeroff et al., 1984), the primary hypothalamic factor driving stress-induced adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary.”
BackgroundLolait, S. J., O'Carroll, A.-M., McBride, O. W., Konig, M., Morel, A., & Brownstein, M. J. (1992) · Nature · doi:10.1038/357336a0 · Cited by 524 · cited 1×
“AVP binds specifically to the V1A, V1B and V2 receptors (for receptor nomenclature see Alexander et al., 2013) to exert its physiological effects (Antoni, 1984; Lolait et al., 1992; Morel et al., 1992).”
BackgroundMolecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471 · cited 1×
“…was highlighted in reports that a V1B receptor antagonist, SSR149415, exhibits antidepressant and anxiolytic effects in several animal models of depression and anxiety, particularly under high-stress conditions (Griebel et al., 2002; Serradeil-Le Gal et al., 2002; Overstreet and Griebel, 2005).”
BackgroundPurba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Aguilera, G., & Rabadan-Diehl, C. (2000) · Regulatory Peptides · doi:10.1016/s0167-0115(00)00196-8 · Cited by 375 · cited 2×
“AVP is linked to the activation of the HPA axis, and the expression level of AVP in the paraventricular nucleus is increased by both acute and repeated stress (Berkenbosch et al., 1989; Aguilera and Rabadan-Diehl, 2000).”
BackgroundPlasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254
Self-citation
Cited by
Mikulska, J., Juszczyk, G., Gawrońska-Grzywacz, M., & Herbet, M. (2021) · Brain Sciences · doi:10.3390/brainsci11101298 · Cited by 450
Rigney, N., Whylings, J., Mieda, M., de Vries, G. J., & Petrulis, A. (2019) · eNeuro · doi:10.1523/eneuro.0415-18.2019 · Cited by 63
“, 2017) or tended to focus on stress-related or aggressive vocalizations across development (Winslow and Insel, 1993; Bleickardt et al., 2009; Iijima et al., 2014; Lukas and Wöhr, 2015; Paul et al., 2016; Freeman et al., 2018).”
BackgroundNeuropeptide systems and new treatments for nicotine addiction
Bruijnzeel, A. W. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4513-5 · Cited by 36
Vasopressin V1B receptor antagonists as potential antidepressants
Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34
Self-citationKamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28
Self-citation
Metadata
- Authors
- Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-06-25
- Volume
- 171
- Issue
- 14
- Pages
- 3511-3525
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1524018505
- Cited by
- 55
- References
- 14
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP 0233278 and TASP 0390325. https://app.cochat.ai/papers/10.1111/bph.12699
- The paper
- Iijima, M., Yoshimizu, T., Shimazaki, T., Tokugawa, K., Fukumoto, K., Kurosu, S., Kuwada, T., Sekiguchi, Y., & Chaki, S. (2014). Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP 0233278 and TASP 0390325. British Journal of Pharmacology. https://doi.org/10.1111/bph.12699
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.